Company news
Eloxx Pharmaceuticals, Inc. (OTC:ELOX) news
Eloxx Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 14, 2026: Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study…
Press releases & updates
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
September 14, 2026
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
November 12, 2024
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
July 11, 2024
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
April 16, 2024
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
November 13, 2023
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction
October 10, 2023
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
October 9, 2023
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 19, 2023
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
September 18, 2023
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
September 7, 2023
Eloxx Pharmaceuticals : Management Change - Form 8-K
August 29, 2023
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
August 15, 2023
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
August 14, 2023
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
August 14, 2023
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
August 3, 2023
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
July 10, 2023
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study
June 29, 2023
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
June 28, 2023
ELOXX PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
June 23, 2023
Eloxx Pharmaceuticals Announces Uplisting to Nasdaq and Pricing of $50 Million Public Offering of Common Stock
April 25, 2018
Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock
April 24, 2018
Eloxx Pharmaceuticals Announces that Two Abstracts for ELX-02 Have Been Accepted for Presentation at the 41st European Cystic Fibrosis Conference
April 18, 2018
Eloxx Pharmaceuticals Reports Full Year 2017 Financial and Operating Results and Provides Business Update
March 19, 2018
Eloxx Pharmaceuticals Chairman and CEO Robert Ward to Participate in a Panel Discussion at the Biotech Showcase 2018 Conference
January 4, 2018
UPDATE -- Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer
December 27, 2017
Sevion Therapeutics Announces 1-for-20 Reverse Stock Split
December 19, 2017
Eloxx Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial
November 27, 2017
Eloxx Pharmaceuticals Announces Expansion of Intellectual Property Estate for ELX-02 with Newly Granted Patent in Europe
October 16, 2017
Eloxx Pharmaceuticals Appoints Gregory Weaver as Chief Financial Officer
September 26, 2017
Eloxx Pharmaceuticals Expands Management Team to Support Rapid Development of Lead Drug Candidate ELX-02 for the Treatment of Rare Genetic Diseases
September 8, 2017
Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 million
August 2, 2017
Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis
June 26, 2017
Sevion Therapeutics Inc. and Eloxx Pharmaceuticals Ltd Announce the Entering into of an Acquisition Transaction
June 2, 2017
Harlan Waksal, M.D. resigns as Chairman of the Board of Sevion Therapeutics
March 10, 2016
Sevion Therapeutics Reports First Quarter 2016 Financial Results
November 17, 2015
Sevion Therapeutics Presents Cow Antibody Platform at Protein Discovery Summit
October 21, 2015
Sevion Therapeutics Reports Fiscal Year 2015 Financial Results
October 14, 2015
Sevion Therapeutics Presents Antibody Discovery Platform at International Conference
September 22, 2015
Sevion Therapeutics, Inc. Announces Close of Private Placement Financing for Gross Proceeds of Approximately $6.55 Million
August 3, 2015
Sevion Therapeutics Announces Establishment of a Biophysical Characterization Applications Lab
July 30, 2015
Sevion Therapeutics Announces Immuno Oncology Discovery Program at BIO
June 16, 2015
Sevion Therapeutics to Present at International Antibody Meeting
June 5, 2015
Sevion Therapeutics to Present at 2015 BIO International Convention
June 3, 2015
Sevion Therapeutics Reports Third Quarter 2015 Financial Results
May 15, 2015
Sevion Therapeutics Presents Cow Antibody Platform at PEGS 2015
May 4, 2015
Sevion Therapeutics Reports Second Quarter 2015 Financial Results
February 18, 2015
Sevion Announces Antibody Discovery Collaboration with Johnson & Johnson Innovation and Janssen
December 22, 2014
Sevion Therapeutics Presents Results of SNS01-T Phase 1b/2a Dose Escalation Study at ASH Annual Meeting
December 8, 2014
Sevion Therapeutics Announces Chimerasome Research Agreement
November 24, 2014